萬里馬(300591.SZ):預中標南航採購項目
格隆匯7月31日丨萬里馬(300591.SZ)公佈,2025年7月30日,中國南航集團進出口貿易有限公司(招標代理機構)在中國南方航空採購招標網上發佈了《2025-2026年南航綜合保障部空勤箱包採購項目評標公示》,對項目中標候選人進行了公示,公示期於2025年8月2日屆滿。廣東萬里馬實業股份有限公司成爲中國南方航空股份有限公司2025-2026年南航綜合保障部空勤箱包採購項目的預中標單位。
根據公示評標結果、招標規模及預測採購量,公司中標金額預計爲4,383.50萬元左右。合同期內的採購數量可能會有所增減,採購單價不進行調整。最終以實際簽訂的採購合同、訂單爲準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.